Revvity, Inc. · NYSE:RVTY

Revvity — Investor Day (November 2026)

91 slides from Revvity's investor day presentation, Nov 13, 2026

  1. Slide 1: Investor Day 2026

    Slide 1: Investor Day 2026

    ©2026 Revvity, Inc.©2026 Revvity, Inc. All rights reserved. Powering scientific intelligence Transforming insight into impact INVESTOR DAY 2026 | November 13

  2. Slide 2: Welcome and Opening Remarks

    Slide 2: Welcome and Opening Remarks

    Welcome and Opening Remarks Steve Willoughby Senior VP, Investor Relations, ESG, Risk ©2026 Revvity, Inc.

  3. Slide 3: Safe Harbor

    Slide 3: Safe Harbor

    ©2026 Revvity, Inc. Safe Harbor 3 This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue grow

  4. Slide 4: Financial Disclosures

    Slide 4: Financial Disclosures

    ©2026 Revvity, Inc. 4 Financial Disclosures Estimated future results and historical growth rates presented and discussed today are based on 2026 pro forma guidance as provided on November 3, 2026 (2026E) and exclude: • Immunodiagnostics business in China which is currently under a definitive agreeme

  5. Slide 5: Agenda

    Slide 5: Agenda

    ©2026 Revvity, Inc. i , I . Agenda Steve Willoughby | Senior VP, Investor Relations, ESG, RiskWelcome1 Prahlad Singh, PhD | President and CEO Company Overview2 Kevin Willoe | President, Signals SoftwareSignals Software Overview3 Craig Monell, PhD | Senior VP, Reagents David Gosalvez, PhD | Chief Str

  6. Slide 6: Powering scientific intelligence

    Slide 6: Powering scientific intelligence

    Powering scientific intelligence Prahlad Singh, PhD President and CEO ©2026 Revvity, Inc.

  7. Slide 7: Our purpose

    Slide 7: Our purpose

    ©2026 Revvity, Inc. Expanding the boundaries of human potential through science Our purpose 7 Revolutionizing science and transforming human lives through groundbreaking innovation

  8. Slide 8: An innovative and differentiated Life Sciences and Diagnostics company

    Slide 8: An innovative and differentiated Life Sciences and Diagnostics company

    ©2026 Revvity, Inc. 8 i , I . Strong positions in specialty clinical areas Unique reagents, instruments and software capabilities Driving faster and deeper experimentation and learning We are an innovative and differentiated Life Sciences and Diagnostics company Bringing together scientific data, co

  9. Slide 9: Revvity at-a-glance

    Slide 9: Revvity at-a-glance

    ©2026 Revvity, Inc. Revvity at-a-glance 9 2026E Revenue: ~$2.9B Segments Geography ~45% Americas ~20% APAC ~35% EMEA ~85% Recurring Revenue* ~15% Non-recurring Revenue ~55% Life Sciences ~45% Diagnostics Powered by ~10,000 employees collaborating to pioneer groundbreaking solutions *Consumables, ser

  10. Slide 10: Diagnostics at-a-glance

    Slide 10: Diagnostics at-a-glance

    ©2026 Revvity, Inc. Diagnostics at-a-glance 10 $30B+ Addressable market MSD 5-year market CAGR Broad portfolio in specialty areas spanning newborn, autoimmune and infectious disease screening ~55% Immunodiagnostics ~45% Reproductive Health Segment Revenue (2026E) ~$1.4B ~90% Recurring Revenue Strong

  11. Slide 11: Immunodiagnostics at-a-glance

    Slide 11: Immunodiagnostics at-a-glance

    ©2026 Revvity, Inc. Immunodiagnostics at-a-glance 11 Autoimmune A global leader with broad testing menu Infectious disease Continuing to improve positioning in this high-growth market Specialized, high-growth Immunodiagnostics business Strong positions in: ~60% Autoimmune ~35% Infectious disease ~5%

  12. Slide 12: Highlighting our Immunodiagnostics portfolio

    Slide 12: Highlighting our Immunodiagnostics portfolio

    ©2026 Revvity, Inc. Highlighting our Immunodiagnostics portfolio 12 Acute and chronic infectious disease diagnostics across a range of automated throughput needs A comprehensive menu of highly sensitive tests, innovative automation and AI- supported software for non-routine, specialized autoimmune d

  13. Slide 13: Reproductive Health at-a-glance

    Slide 13: Reproductive Health at-a-glance

    ©2026 Revvity, Inc. Reproductive Health at-a-glance 13 40+ years of newborn screening leadership Deep integration across workflows and strong commercial execution support sustainable above-market growth Established global footprint and strong presence in public health NBS programs Revenue (2026E) ~$

  14. Slide 14: Highlighting our Reproductive Health portfolio

    Slide 14: Highlighting our Reproductive Health portfolio

    ©2026 Revvity, Inc. Highlighting our Reproductive Health portfolio 14 Newborn screening Maternal & prenatal health Cord blood banking Multiomics services Offers complete workflow solutions from sample to result. Over 760M infants screened using our advanced technologies Delivers newborn cord blood a

  15. Slide 15: Unique positions in specialty diagnostics

    Slide 15: Unique positions in specialty diagnostics

    ©2026 Revvity, Inc. 15 Our unique positions in specialty diagnostics provide a strong foundation to expand access to more actionable clinical answers

  16. Slide 16: Building a nephrology portfolio with next-generation biomarkers

    Slide 16: Building a nephrology portfolio with next-generation biomarkers

    ©2026 Revvity, Inc. Building a nephrology portfolio with high-value testing and next-generation biomarkers 16 9 in 10 adults who have chronic kidney disease are undiagnosed Expanding our autoimmune portfolio to provide patients with diagnostic answers and help monitor response Driving innovation thr

  17. Slide 17: Shaping the future of newborn screening

    Slide 17: Shaping the future of newborn screening

    ©2026 Revvity, Inc. Shaping the future of newborn screening 17 We offer comprehensive workflows and are a global market leader in dried blood spot testing Continuing to advance newborn screening through complementary approaches Sample collection Extraction and QC Library prep and QC Sequencing servi

  18. Slide 18: Expanding into population screening

    Slide 18: Expanding into population screening

    ©2026 Revvity, Inc. Building on our newborn leadership to expand into population screening 18 Developing a multiplex assay from one dried blood spot Leveraging screening relationships and dried blood spot expertise BioLegend: High-quality, validated reagents Reproductive Health: Commercial scalabili

  19. Slide 19: Bringing together capabilities to advance precision medicine

    Slide 19: Bringing together capabilities to advance precision medicine

    ©2026 Revvity, Inc. Bringing together differentiated capabilities to advance precision medicine 19 Life Sciences DiagnosticsBridging the gap from discovery to cure Applying our portfolio to diverse applications + OncologyRare disease Chronic disease Supporting an innovative customer base

  20. Slide 20: Life Sciences at-a-glance

    Slide 20: Life Sciences at-a-glance

    ©2026 Revvity, Inc. Life Sciences at-a-glance 20 $30B+ Addressable market MSD 5-year market CAGR Portfolio spanning automation, imaging, detection, cellular analysis, reagents and software ~85% Recurring Revenue Consistent track record of innovation and novel IP Integrated solutions help customers g

  21. Slide 21: Signals Software at-a-glance

    Slide 21: Signals Software at-a-glance

    ©2026 Revvity, Inc. Signals Software at-a-glance Leading provider of scientific SaaS Empowering scientists and decision- makers to gain critical insights from data analytics, accelerating informed decisions ~$260M 2026E Revenue 1M+ users across 4,000+ customers worldwide #1 ELN (Electronic Lab Noteb

  22. Slide 22: Reagents at-a-glance

    Slide 22: Reagents at-a-glance

    ©2026 Revvity, Inc. Reagents at-a-glance Offers assays that help customers gain deeper insights into cellular biology Dedicated global Centers of Excellence, supporting reliable supply and faster delivery to customers Unique biomarker development and detection capabilities ~$0.7B Revenue (2026E) ~55

  23. Slide 23: Highlighting our Reagents portfolio

    Slide 23: Highlighting our Reagents portfolio

    ©2026 Revvity, Inc. Highlighting our Reagents portfolio 23 Differentiated biological content, assay technologies and scientific expertise support critical workflows RUO antibodies Research reagents Features reagents and consumables, including antibodies for flow cytometry, recombinant proteins and m

  24. Slide 24: Instruments at-a-glance

    Slide 24: Instruments at-a-glance

    ©2026 Revvity, Inc. Instruments at-a-glance Providing expertise, technology and capabilities from basic research through drug development High-value instruments with complementary reagents and software Automating complex cellular analysis to accelerate research Global instrument Centers of Excellenc

  25. Slide 25: Highlighting our Instruments portfolio

    Slide 25: Highlighting our Instruments portfolio

    ©2026 Revvity, Inc. Highlighting our Instruments portfolio 25 Offers cell counters and high-content screening platforms that provide a fast and accurate way to assess cells Advanced preclinical imaging solutions (i.e. optical, microCT, ultrasound) with user-friendly software that leverages AI integr

  26. Slide 26: Next generation of Life Sciences innovation

    Slide 26: Next generation of Life Sciences innovation

    ©2026 Revvity, Inc. 26 Advancing the next generation of Life Sciences innovation with our unique reagents, instruments and software solutions

  27. Slide 27: Continuous innovation driving sustained growth

    Slide 27: Continuous innovation driving sustained growth

    ©2026 Revvity, Inc. Continuous innovation driving sustained growth 27 Expanding scientists' ability to generate high-quality biological data and accelerate discovery 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Revenue contribution from new LSS reagents by year ~1,500 new reagents, ki

  28. Slide 28: Innovative software drives value across Life Sciences portfolio

    Slide 28: Innovative software drives value across Life Sciences portfolio

    ©2026 Revvity, Inc. Innovative software drives additional value across our Life Sciences portfolio 28 Integrating novel software from across Revvity into the Signals platform, helping researchers answer critical questions while creating differentiated competitive advantages • AI-based, in vivo image

  29. Slide 29: Specialized, high-growth markets, diverse customer base

    Slide 29: Specialized, high-growth markets, diverse customer base

    ©2026 Revvity, Inc. 29 Uniquely positioned in specialized, high-growth markets, serving a diverse customer base Key customers Life Sciences Diagnostics Pharma / Biotech Academia / Government Reference Labs Hospitals / Clinics Public Health Labs ~$1.5B ~85% Life Sciences Solutions ~15% Signals Softwa

  30. Slide 30: What you will hear today

    Slide 30: What you will hear today

    ©2026 Revvity, Inc. What you will hear today 30 Set to deliver compelling long-term value creation Continued confidence in the long-range outlook Revvity is: Positioned for the future of scientific discovery Unique capabilities across biology, measurement and data integration A differentiated portfo

  31. Slide 31: Revvity Signals: Connecting the scientific workflow

    Slide 31: Revvity Signals: Connecting the scientific workflow

    Kevin Willoe President, Signals Software Revvity Signals Connecting the scientific workflow ©2026 Revvity, Inc.

  32. Slide 32: Key Messages

    Slide 32: Key Messages

    ©2026 Revvity, Inc. Key Messages 32 EMBEDDED IN HOW SCIENCE IS DONE Digital system of record connecting scientific workflows from idea to creation MORE VALUABLE AS SCIENCE TRANSFORMS Unified platform enabling customers to realize greater value from accelerated data generation and AI-enabled workflow

  33. Slide 33: What is Revvity Signals?

    Slide 33: What is Revvity Signals?

    ©2026 Revvity, Inc. What is Revvity Signals ? 33 Scientific software that enables teams to plan and carry out research, understand their data and decide what comes next What are we trying to create? How do we carry out the work? What are the results telling us? What should we do next? Develop ideas,

  34. Slide 34: As technology has evolved, Signals has evolved with it

    Slide 34: As technology has evolved, Signals has evolved with it

    ©2026 Revvity, Inc. As technology has evolved… 2015 - 20202000 - 20151985 - 2000 The Birth of Cheminformatics Cheminformatics for the Enterprise Re-platforming for SaaS 2025 and beyond2020 - 2025 SaaS Platform Expansion Operationalizing Scientific AI Personal Computers The Internet SaaS AI ChemDraw

  35. Slide 35: Signals' operating metrics

    Slide 35: Signals' operating metrics

    ©2026 Revvity, Inc. Signals’ operating metrics reflect the recurring, expanding nature of the business… Key software metrics 2020 2026E >$100M ARR Annual recurring revenue Total expected revenue over the next 12 months from SaaS contracts 13% CAGR >$275M >$130M APV Annualized portfolio value Annual

  36. Slide 36: Why customers choose Revvity Signals Software

    Slide 36: Why customers choose Revvity Signals Software

    ©2026 Revvity, Inc. it , I . 36 Why customers choose Revvity Signals Software • Transformational capabilities • Enterprise-grade security • Scientific system of record • Depth & breadth • SaaS done right • Proven at scale 2026 evv y nc

  37. Slide 37: Turning scattered activity into a system of record

    Slide 37: Turning scattered activity into a system of record

    ©2026 Revvity, Inc. Turning scattered scientific activity into a system of record 37 FRAGMENTED SYSTEMS CONNECTED KNOWLEDGE Experiments & protocols Analytics & AI Samples, results & conditions Institutional memory Teams & workflows Samples, results & conditions Experiments & protocols Teams & workfl

  38. Slide 38: Serving scientists across disciplines and R&D lifecycle

    Slide 38: Serving scientists across disciplines and R&D lifecycle

    ©2026 Revvity, Inc. Serving scientists across disciplines and the R&D lifecycle 38 Large Molecule Research Small Molecule Research Formulations Research Testing Assay Development Large Molecule Development Small Molecule Development Formulations Development CMC QA/QC Clinical Trials Analytics AI-Aug

  39. Slide 39: A comprehensive, unified software platform

    Slide 39: A comprehensive, unified software platform

    ©2026 Revvity, Inc. A comprehensive, unified software platform of modularized, transformative solutions 39 Innovative chemical drawing standard for small molecules and biopolymers Advanced scientific analytics and visualization platform Revvity Signals Technology Framework - SaaS done right Novel CR

  40. Slide 40: Delivering unprecedented depth and breadth

    Slide 40: Delivering unprecedented depth and breadth

    ©2026 Revvity, Inc. Delivering unprecedented depth and breadth… 40 Large Molecule Research Small Molecule Research Formulations Research Testing Assay Development Large Molecule Development Small Molecule Development Formulations Development CMC QA/QC Clinical Trials Analytics AI-Augmented Design Re

  41. Slide 41: Streamlining scientific workflows with LabGistics

    Slide 41: Streamlining scientific workflows with LabGistics

    ©2026 Revvity, Inc. Streamlining scientific workflows across the R&D lifecycle with LabGistics 41 Capturing the complexity of scientific work to accelerate it Innovation spotlight: Accelerate technology transfer through seamless handoffs between development and manufacturing processes Simplify regul

  42. Slide 42: Helping scientists answer complex biological questions faster

    Slide 42: Helping scientists answer complex biological questions faster

    ©2026 Revvity, Inc. Helping scientists answer complex biological questions faster 42 A scalable Models- as-a-Service offering that converges with the wet lab Partnership spotlight: Building on Signals One to enable a continuous learning system Transformational Federated Learning platform Innovation

  43. Slide 43: AI-driven transformation expands Signals' opportunity

    Slide 43: AI-driven transformation expands Signals' opportunity

    ©2026 Revvity, Inc. The AI-driven transformation of science further expands Signals’ opportunity Signals has evolved into a broad, connected scientific platform The platform is embedded in customer workflows and serves as a scientific system of record Expansion and innovation have produced a scaled,

  44. Slide 44: The New Era of Scientific Discovery

    Slide 44: The New Era of Scientific Discovery

    The New Era of Scientific Discovery Where AI-driven design meets biological evidence ©2026 Revvity, Inc. Craig Monell, PhD Senior VP, Reagents David Gosalvez, PhD Chief Strategy Officer, Signals Software

  45. Slide 45: Key Messages

    Slide 45: Key Messages

    ©2026 Revvity, Inc. i , I . 45 Key Messages AI is driving the next era of scientific discovery DISCOVERY IS ACCELERATING More high-quality biological data will enable increased exploration, better prediction and faster prioritization BIOLOGY STILL DECIDES Experimental evidence determines what works

  46. Slide 46: Drug discovery entering a new era as AI expands

    Slide 46: Drug discovery entering a new era as AI expands

    ©2026 Revvity, Inc. i , I . 46 Drug discovery is entering a new era as AI expands both the scale and value of scientific data As AI expands discovery, high-quality biological data becomes increasingly important for validating hypotheses, generating new insights, and guiding scientific decisions ▪ Ex

  47. Slide 47: Historically, discovery was constrained by exploration

    Slide 47: Historically, discovery was constrained by exploration

    ©2026 Revvity, Inc. i , I . 47 Historically, discovery was constrained by how much scientists could explore Previous Bottleneck Test Measure ValidateGenerate Predict Prioritize Physical Biology Screen, reveal, test and validate biology The challenge was identifying the most promising opportunities f

  48. Slide 48: AI accelerating how scientists analyze and learn

    Slide 48: AI accelerating how scientists analyze and learn

    ©2026 Revvity, Inc. i , I . 48 AI is accelerating how scientists analyze and learn from scientific data Faster analysis and learning increase demand for decision-grade biological evidence, shifting the constraint toward evidence generation Larger, more complex datasets can be analyzed faster, shorte

  49. Slide 49: Need for richer biological evidence increases

    Slide 49: Need for richer biological evidence increases

    ©2026 Revvity, Inc. i , I . 49 As discovery accelerates, the need for richer biological evidence increases In-Silico (“Virtual Lab”) Explore more, faster Physical Biology (“Wet Lab”) Reveal, test and validate biology Emerging Bottleneck Test Measure ValidateGenerate Predict Prioritize As more promis

  50. Slide 50: Candidates require robust biological validation

    Slide 50: Candidates require robust biological validation

    ©2026 Revvity, Inc. i , I . Promising candidates require robust biological validation before they advance HOW DOES IT WORK? Understand cellular response DOES IT WORK? Validate biological function WHAT ELSE DOES IT AFFECT? Assess selectivity and safety No single readout tells the whole biological sto

  51. Slide 51: Computational discovery depends on high-quality experimental data

    Slide 51: Computational discovery depends on high-quality experimental data

    ©2026 Revvity, Inc. i , I . 51 The next generation of computational discovery depends on high-quality experimental data… …requiring more from wet lab experimentation to inform what comes next RICHER DATA BETTER MODELS Updated with new, high-quality experimental evidence USABLE DATA BETTER PREDICTION

  52. Slide 52: Revvity brings together biology, technologies and connected data

    Slide 52: Revvity brings together biology, technologies and connected data

    ©2026 Revvity, Inc. i , I . 52 Revvity brings together biological expertise, innovative technologies and connected data Our portfolio helps scientists characterize biological responses from multiple angles, generating high-quality data and enabling a faster, more informed cycle of prediction, valida

  53. Slide 53: Unique reagents and instruments enable richer experimentation

    Slide 53: Unique reagents and instruments enable richer experimentation

    ©2026 Revvity, Inc. i , I . 53 Our unique reagents and instruments enable faster, richer and more informative experimentation

  54. Slide 54: Critical tools generating data powering AI-enabled science

    Slide 54: Critical tools generating data powering AI-enabled science

    ©2026 Revvity, Inc. Revvity provides critical tools that generate the biological data powering AI-enabled science 54 Foundational enablers Data-rich differentiators Multimode plate readers Increase the speed and efficiency of experimentation Increase the information captured from each experiment Aut

  55. Slide 55: Validating more promising candidates

    Slide 55: Validating more promising candidates

    ©2026 Revvity, Inc. Validating more promising candidates 55 Multimode plate readers and no-wash assays streamline routine screening and help scientists test more possibilities with greater speed and efficiency Foundational enablers High-performance assay technologies HTRF / AlphaLISA Scalable detect

  56. Slide 56: Understanding how cells respond

    Slide 56: Understanding how cells respond

    ©2026 Revvity, Inc. Understanding how cells respond 56 High-content screening captures rich visual information to show how individual cells change and respond across many conditions Data-rich differentiators Capture more biological detail High-parameter reagents reveal more features in each experime

  57. Slide 57: Understanding responses of cell populations

    Slide 57: Understanding responses of cell populations

    ©2026 Revvity, Inc. Understanding responses of cell populations 57 High-dimensional flow cytometry helps scientists see which cell populations respond and how strongly they respond in both cellular models and living subjects Data-rich differentiators Detect subtle cell populations Brighter signals w

  58. Slide 58: Revvity is a critical enabler of wet lab experimentation

    Slide 58: Revvity is a critical enabler of wet lab experimentation

    ©2026 Revvity, Inc. Revvity is a critical enabler of wet lab experimentation 58 Faster experimentation Richer biological data More usable evidence As discovery generates more possibilities, our solutions help scientists generate the data and evidence needed to determine what advances and inform what

  59. Slide 59: Software turns data into insight

    Slide 59: Software turns data into insight

    ©2026 Revvity, Inc. i , I . … Software turns data into insight for what comes next Generating more biological data is only part of the opportunity… 59

  60. Slide 60: Fragmented software supported in-silico and wet lab separately

    Slide 60: Fragmented software supported in-silico and wet lab separately

    ©2026 Revvity, Inc. i , I . 60 Traditionally, fragmented software offerings supported in-silico and wet lab experimental discovery separately Generate Predict vScreen V al id at e Design M ake Test D ec id e AI IN-SILICO DESIGN CYCLE TRADITIONAL WET LAB APPROACH Limited experimental feedback Sparse

  61. Slide 61: AI making the in-silico design cycle more powerful

    Slide 61: AI making the in-silico design cycle more powerful

    ©2026 Revvity, Inc. i , I . 61 AI is making the in-silico design cycle dramatically more powerful… Generate Predict vScreen V al id at e …But a faster design loop is only as valuable as the experimental evidence and context it can connect back to GENERATE AT GREATER SCALE Explore more molecules and

  62. Slide 62: Connecting models and experimental evidence

    Slide 62: Connecting models and experimental evidence

    ©2026 Revvity, Inc. i , I . 62 Scientists need a way to connect models and experimental evidence… …into one continuous learning system IN-SILICO Generate and prioritize hypotheses PHYSICAL BIOLOGY Test and generate experimental evidence TM

  63. Slide 63: Signals driving convergence of AI design and biological validation

    Slide 63: Signals driving convergence of AI design and biological validation

    ©2026 Revvity, Inc. Revvity Signals software is driving the convergence of AI design and biological validation 63 One connected environment to plan experiments, capture scientific work, connect experimental data and inform the next decision The customer’s scientific process from idea to decision Ide

  64. Slide 64: Our software connects data, context and scientific insights

    Slide 64: Our software connects data, context and scientific insights

    ©2026 Revvity, Inc. Our software connects data, context and scientific insights Signals transforms experimental evidence into actionable insights AI is amplifying the value of high-quality biological data More powerful models increasingly depend on rich experimental evidence Our instruments and reag

  65. Slide 65: Driving Operational Success and Creating Long-Term Value

    Slide 65: Driving Operational Success and Creating Long-Term Value

    Driving Operational Success and Creating Long-Term Value Max Krakowiak Senior VP, CFO ©2026 Revvity, Inc.

  66. Slide 66: Key Messages

    Slide 66: Key Messages

    ©2026 Revvity, Inc. Key Messages 66 DIFFERENTIATED FINANCIAL PERFORMANCE Ability to deliver strong results across varying market environments OPERATIONAL EXCELLENCE Driving margin expansion, earnings growth and free cash flow ATTRACTIVE LONG-TERM POTENTIAL Durable growth powered by innovation and ex

  67. Slide 67: We have navigated a dynamic environment

    Slide 67: We have navigated a dynamic environment

    ©2026 Revvity, Inc. We have navigated a dynamic environment… 67 Post-COVID normalization 3 successive waves of market disruptions Pharma / Biotech market pressure Geopolitical and policy uncertainty 2023 2024 2025

  68. Slide 68: Strong and above-market financial performance since 2022

    Slide 68: Strong and above-market financial performance since 2022

    ©2026 Revvity, Inc. …Yet, since 2022, we delivered strong and above- market financial performance 68 Adj. Revenue $2B Capital deployed 0.6x Net leverage decrease 12% Reduction in share count Key Highlights Since 2022 Adj. EPS Adj. Operating Margin ~28.8% Free Cash Flow >90% FCF conversion>$575M 2026

  69. Slide 69: Driving execution through the Revvity Operating Model

    Slide 69: Driving execution through the Revvity Operating Model

    ©2026 Revvity, Inc. Driving execution through the Revvity Operating Model 69 Strategic Priorities Efficiency Capturing AI-enabled productivity gains1 Simplification Creating a nimbler organization 2 Optimization Streamlining our operations3 Talent < Digitalization Agility Accountability Our Operatin

  70. Slide 70: Efficiency: Capturing AI-enabled productivity gains

    Slide 70: Efficiency: Capturing AI-enabled productivity gains

    ©2026 Revvity, Inc. Efficiency: Capturing AI-enabled productivity gains 70 In the past Software engineering capacity was a key bottleneck in product development Today at Revvity Limited engineering bandwidth Longer development cycle Slower time to market Unlocking speed and impact through AI-enabled

  71. Slide 71: Simplification: Creating a nimbler organization

    Slide 71: Simplification: Creating a nimbler organization

    ©2026 Revvity, Inc. 71 Simplification: Creating a nimbler organization From 2023 to 2026 ~16% reduction in headcount Delayering of management structure to drive efficiency Advancing integration initiatives to capture synergies Driving commercial and operational synergies across LS and Dx

  72. Slide 72: Optimization: Streamlining our operations

    Slide 72: Optimization: Streamlining our operations

    ©2026 Revvity, Inc. 72 Optimization: Streamlining our operations ~25% Global square footage reduction Optimize the network Consolidating packaging and shipping lanes to drive logistics improvements Reduce structural cost Insourcing, product re-engineering and vendor consolidation to lower inventory

  73. Slide 73: Executing our Revvity Operating Model

    Slide 73: Executing our Revvity Operating Model

    ©2026 Revvity, Inc. Executing our Revvity Operating Model… 73 …to drive long-term value creation TalentDigitalizationAgilityAccountability

  74. Slide 74: Our Attractive Long-Term Potential

    Slide 74: Our Attractive Long-Term Potential

    ©2026 Revvity, Inc. i , I . Our Attractive Long-Term Potential

  75. Slide 75: Differentiated performance across dynamic market environments

    Slide 75: Differentiated performance across dynamic market environments

    ©2026 Revvity, Inc. Delivered differentiated performance across dynamic market environments… 75 CAGR since becoming Revvity Life Sciences Solutions -LSD Immunodiagnostics +HSD Reproductive Health +MSD Signals Software +LDD ~20% ~25% ~10% ~45% ~$2.9B Revenue (2026E) Total Dx: +MSD Total LS: Flat Tota

  76. Slide 76: Diagnostics: Innovation driving durable growth

    Slide 76: Diagnostics: Innovation driving durable growth

    ©2026 Revvity, Inc. 76 Diagnostics: Strong innovation and competitive advantages driving durable growth across specialty areas

  77. Slide 77: Immunodiagnostics scaling through innovation and geographic reach

    Slide 77: Immunodiagnostics scaling through innovation and geographic reach

    ©2026 Revvity, Inc. Underlying market growth 500bps 200bps 100bps Geographic penetration Immunodiagnostics is scaling through innovation and geographic reach 77 Growth drivers 7-9% LRP organic growthInnovation Specialty diagnostics solutions with increasing automation and more actionable insights St

  78. Slide 78: Reproductive Health growth drivers

    Slide 78: Reproductive Health growth drivers

    ©2026 Revvity, Inc. 78 Deeper menu and geographic expansion to support future growth Above-market growth enabled by an unparalleled newborn screening solutions portfolio Key messages Reproductive Health Reproductive Health growth is driven by menu expansion and adoption Growth drivers 3-5% LRP organ

  79. Slide 79: Diagnostics Segment long-term outlook

    Slide 79: Diagnostics Segment long-term outlook

    ©2026 Revvity, Inc. 79 5-7% LRP organic growth Long-term outlook 7-9% 3-5% Long-term outlook ~55% of Dx ~45% of Dx Diagnostics Segment: Innovation and execution providing strong growth in specialized markets Immunodiagnostics Reproductive Health Delivering novel innovations in new markets by leverag

  80. Slide 80: Life Sciences: Advancing discovery through connected workflows

    Slide 80: Life Sciences: Advancing discovery through connected workflows

    ©2026 Revvity, Inc. 80 Life Sciences: Advancing discovery through connected workflows with data-rich instruments, specialized reagents and innovative software i , I .

  81. Slide 81: Life Sciences Solutions above-market growth

    Slide 81: Life Sciences Solutions above-market growth

    ©2026 Revvity, Inc. Life Sciences Solutions above-market growth driven by strong positioning and innovation Underlying market growth 500bps 100bps 100bps Downstream expansion 81 Growth drivers 6-8% LRP organic growth Innovation Data-rich solutions that support the discovery and validation of fundame

  82. Slide 82: Signals poised to grow through customer-centric innovations

    Slide 82: Signals poised to grow through customer-centric innovations

    ©2026 Revvity, Inc. 82 Signals is poised to grow through customer-centric innovations and solutions Expansion with existing customers 500bps 300bps 300bps New customer wins Growth drivers 10-12% APV LRP New offerings Robust innovation, scaled and entrenched platform driving sustainable long-term gro

  83. Slide 83: Life Sciences Segment long-term outlook

    Slide 83: Life Sciences Segment long-term outlook

    ©2026 Revvity, Inc. 83 7-9% LRP organic growth Long-term outlook 6-8% 10-12% Long-term outlook Life Sciences Solutions Signals ~85% of LS ~15% of LS Innovative specialty scientific solutions with above-market growth and attractive margins Key messages Life Sciences Segment: Delivering novel biologic

  84. Slide 84: LRP Organic Growth

    Slide 84: LRP Organic Growth

    ©2026 Revvity, Inc. LRP Organic Growth Confident in our ability to deliver above-market growth over the long term 84 Life Sciences Solutions 6-8% Immunodiagnostics 7-9% Reproductive Health 3-5% Signals Software 10-12% ~20% ~25% ~10% ~45% ~$2.9B Revenue (2026E) Total Dx: 5-7% Total LS: 7-9% 6-8% 200b

  85. Slide 85: Achieving top-tier margins

    Slide 85: Achieving top-tier margins

    ©2026 Revvity, Inc. 85 Achieving top- tier margins with industry-leading potential ~28.8% Adj. Operating Margin (%) 2026E Gross margin expansion FutureSG&A operating leverage and cost efficiencies 25bps per year 50bps per year Mid 30s% Incremental adj. op. margins in the low 40s%

  86. Slide 86: Strong long-term financial outlook

    Slide 86: Strong long-term financial outlook

    ©2026 Revvity, Inc. 86 Strong and differentiated long-term financial outlook 75bps operating margin expansion 3% Organic revenue growth (200bps above market) 6-8% Double Digits Adj. EPS growth With several areas for potential upside

  87. Slide 87: Disciplined capital deployment

    Slide 87: Disciplined capital deployment

    ©2026 Revvity, Inc. Complemented by disciplined capital deployment 87*Future capital allocation will vary to target highest-return opportunities Buybacks Dividends M&A Historical (2023-2026E) Future Intentions* (2027-2031) Targeted M&A to complement capabilities across Life Sciences Consistent share

  88. Slide 88: Areas of potential upside beyond the LRP

    Slide 88: Areas of potential upside beyond the LRP

    ©2026 Revvity, Inc. Areas of potential upside beyond the LRP Outsized AI-driven demand Additional strategic partnerships Disciplined and opportunistic capital deployment 88

  89. Slide 89: 2027 considerations

    Slide 89: 2027 considerations

    ©2026 Revvity, Inc. ~6% organic growth ~200bps above market growth ~20bps in addition to normal operating leverage Net Interest = ~$85M Tax Rate = ~19% Share Count = Flat Formal 2027 guidance to be provided on our Q4 earnings call Organic Growth Margin Expansion Below the Line 2027 considerations 89

  90. Slide 90: Key messages from today

    Slide 90: Key messages from today

    ©2026 Revvity, Inc. Key messages from today 90 Powering Scientific Intelligence by bringing together biological expertise, innovative technologies and connected data Revvity is: Revolutionizing science and transforming human lives through groundbreaking innovation Delivering compelling long-term val

  91. Slide 91: i , I .

    Slide 91: i , I .

    ©2026 Revvity, Inc. i , I .

Source: SEC EDGAR · 8-K filed Nov 13, 2026

More decks from Revvity, Inc.

All 34 Revvity decks